Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CARTEOLOL vs CASIRIVIMAB\IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CARTEOLOL vs CASIRIVIMAB\IMDEVIMAB: Safety Overview

Metric CARTEOLOL CASIRIVIMAB\IMDEVIMAB
Total FAERS Reports 318 4,248
Deaths Reported 30 137
Death Rate 9.4% 3.2%
Hospitalizations 93 1,351
Average Patient Age 67.5 yrs 54.3 yrs
% Female Patients 56.6% 55.4%
FDA Approval Date Dec 28, 1988 N/A
Manufacturer Sandoz Inc N/A
Route OPHTHALMIC N/A
Marketing Status Discontinued N/A